Spray-Dried Biologics Market Report 2026

The spray-dried biologics market size has grown rapidly in recent years. It will grow from $1.86 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to advancements in biologics formulation science, increasing biologic drug approvals, need for improved drug stability, expansion of vaccine manufacturing capacity, adoption of advanced pharmaceutical processing technologies.

The spray-dried biologics market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing demand for non-injectable biologics, rising investments in dry powder delivery systems, expansion of global vaccine production, growing focus on cold-chain reduction, advancements in spray-drying equipment design. Major trends in the forecast period include increasing adoption of spray-drying for biologic stability, rising demand for inhalable and oral biologic formulations, expansion of continuous spray-drying processes, growing use of dry powder biologics in vaccines, enhanced focus on shelf-life extension.

Rising demand for biopharmaceuticals is anticipated to fuel expansion in the spray-dried biologics market. Biopharmaceuticals consist of therapeutic products sourced from biological origins, such as living cells, proteins, and various biomolecules. The need for biopharmaceuticals is growing amid a worldwide increase in chronic and complex diseases, heightening the demand for treatments with greater precision, enhanced effectiveness, and reduced systemic side effects. The spray-dried biologics sector is seeing heightened interest as the swift growth of biopharmaceuticals pushes firms toward scalable formulation methods that boost stability, extend shelf life, and optimize delivery. For example, in February 2025, the World Health Organization (WHO), a Switzerland-headquartered global public health body, reported that its 2023 essential medicines list (EML) featured 81 biologic therapies, representing over 15% of all essential medicines. Thus, the surging demand for biopharmaceuticals is propelling the spray-dried biologics market forward.

Major companies in the spray-dried biologics market are prioritizing technological innovations like drum dosing technology to boost dose precision, powder handling effectiveness, and dependable high-volume capsule filling. Drum dosing technology represents a sophisticated powder-filling technique that employs a rotating drum equipped with precisely designed dosing cavities and vacuum-assisted transfer to meter and place dry powders into capsules with high accuracy, supporting features such as uniform low-dose filling, better flow control for spray-dried powders, and scalable high-throughput operations. For example, in February 2024, Catalent Inc., a US-based contract development and manufacturing organization (CDMO), enhanced its inhalation manufacturing facility in the US by integrating potent capsule-filling capabilities driven by drum-based dosing systems and in-line advanced mass verification. The upgraded platform accommodates precise filling of engineered and spray-dried powders, incorporating real-time dose validation and controlled low-humidity processing. This improvement boosts manufacturing efficiency, product uniformity, and preparedness for commercial-scale production of spray-dried biologic dry-powder inhalation therapies.

In May 2023, Hovione, a Portugal-based integrated contract development and manufacturing organization (CDMO) focused on spray drying and particle engineering, teamed up with H&T Presspart to advance high-efficiency device technology for delivering dry powder inhalation formulations. This partnership allows Hovione to strengthen its expertise in engineered spray-dried and high-dose inhalation formulations by utilizing Presspart’s Sunriser capsule-based dry powder inhaler platform, which boosts the performance and market readiness of inhalation therapies.

Major companies operating in the spray-dried biologics market are Thermo Fisher Scientific Inc., Evonik Industries AG, Lonza Group AG, GEA Group, Fareva Group, Almac Group Limited, Seqens Group, Fabbrica Italiana Sintetici S.p.A., CordenPharma International, Hovione FarmaCiencia SA, Veranova Inc., Pace Analytical Services LLC, Olon S.p.A., Nova Laboratories Ltd, Leukocare AG, Micro Sphere SA, Seran Bioscience LLC, CritiTech Particle Engineering Solutions LLC, Xedev BV, BÜCHI Labortechnik AG.

North America was the largest region in the spray-dried biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spray-dried biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spray-dried biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the spray-dried biologics market by increasing costs of imported spray dryers, stainless steel processing components, filtration systems, and analytical instruments used in biologic drug manufacturing. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces higher capital costs for facility expansion. These tariffs are raising production expenses and slowing capacity additions. At the same time, they are encouraging localized equipment manufacturing, regional supply partnerships, and investment in domestic biologics processing infrastructure.

The spray-dried biologics market research report is one of a series of new reports that provides spray-dried biologics market statistics, including spray-dried biologics industry global market size, regional shares, competitors with a spray-dried biologics market share, detailed spray-dried biologics market segments, market trends and opportunities, and any further data you may need to thrive in the spray-dried biologics industry. This spray-dried biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spray-dried biologics are biologic drugs that have been converted from a liquid into a dry powder through a rapid drying method. The process involves spraying the liquid formulation into heated air, which rapidly eliminates moisture while preserving the integrity of sensitive components such as proteins, vaccines, or enzymes. The resulting dry form provides benefits such as improved stability, easier handling, and compatibility with various delivery routes.

The primary product categories for spray-dried biologics encompass monoclonal antibodies, vaccines, enzymes, hormones, and additional types. Monoclonal antibodies consist of lab-engineered molecules that precisely identify and attach to particular target antigens. The various administration methods include oral, inhalation or pulmonary, injectable, and topical routes, which cater to end-users like hospitals, research institutes, pharmaceutical and biotechnology companies, and others.

The spray-dried biologics market consists of sales of peptide therapeutics, deoxyribonucleic acid vaccines, ribonucleic acid vaccines, nanobodies, antibody-drug conjugates, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.